Uncover key drivers, emerging technologies, and competitive movements shaping the endocrine testing market from 2026–2035 with trusted insights from The Business Research Company
What total market size is anticipated for the Endocrine Testing Market in 2030?
The endocrine testing market size has seen significant growth in recent years. It is forecast to increase from $2.79 billion in 2025 to $3.05 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. The expansion observed in the historic period can be ascribed to diabetes prevalence, thyroid disorder incidence, clinical laboratory expansion, hormone testing awareness, and chronic disease diagnostics growth.
The endocrine testing market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $4.15 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. This expansion during the forecast period can be attributed to a sharpened focus on preventive healthcare, personalized treatment planning, greater automation in hormone testing, the broadening of diagnostic centers, and various endocrine disease screening programs. Significant developments expected in the forecast period include the increasing prevalence of hormonal disorders, wider adoption of comprehensive hormone panels, an expansion of preventive endocrine screening, a growing need for accurate diagnostic results, and the integration of advanced diagnostic technologies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15562&type=smp
What Drivers Are Influencing Production Trends In The Endocrine Testing Market?
An anticipated increase in the incidence of diabetes is set to drive expansion within the endocrine testing market in the future. Diabetes encompasses a collection of conditions characterized by elevated levels of blood sugar (glucose). The growing occurrence of diabetes is attributed to elements like poor dietary habits, inactive lifestyles, genetic susceptibility, and a demographic shift towards an older population. In the context of diabetes, endocrine testing – which includes tests such as hemoglobin A1c, fasting plasma glucose, and C-peptide – serves to diagnose the illness, track glucose concentrations, and evaluate insulin generation and responsiveness. For example, data from June 2024, published by the National Health Service (NHS), a UK-based government department, indicated a rise in cases among individuals under 40, escalating from 173,166 in 2022 to 216,440 in 2023. This considerable expansion underscores a worrying pattern within this demographic. The figures demonstrate a swift increase in the occurrence of diabetes within younger age groups. Consequently, the increasing prevalence of diabetes is a key driver for the endocrine testing market.
Which Segment Groups Are Influencing The Endocrine Testing Market?
The endocrine testing market covered in this report is segmented –
1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types
2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users
Subsegments:
1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test
2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test
3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test
4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test
5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test
6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test
7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test
8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test
9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test
10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test
Which Innovation Trends Are Advancing Developments Within The Endocrine Testing Market?
Major companies in the endocrine testing market are innovating point-of-care (POC) testing solutions to improve the accessibility and efficiency of diagnosing endocrine disorders. POC testing delivers rapid results, which can support the swift diagnosis and management of heart failure in patients experiencing symptoms such as shortness of breath and fatigue. For instance, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical firm, launched a point-of-care NT-proBNP test in India, specifically tailored for screening diabetes patients prone to cardiovascular diseases, like heart failure (HF). This allows for early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely discussions regarding treatment, ultimately promoting enhanced outcomes and patient well-being.
Who Are The Core Companies Influencing Trends In The Endocrine Testing Market?
Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report
Which Geographic Areas Are Emerging As Strong Markets For The Endocrine Testing Market?
North America was the largest region in the endocrine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Endocrine Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15562&type=smp
Browse Through More Reports Similar to the Global Endocrine Testing Market 2026, By The Business Research Company
Thyroid Function Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report
Endocrine Peptide Test Market Report 2026
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report
Hormone Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model